-
Qiao, N.; Li, M.; Schlindwein, W.; Malek, N.; Davies, A.; Trappitt, Pharmaceutical cocrystals: an overview, G. Int. J. Pharm. 2011, 419 (1), 1−11.
-
Good, D. J.; Rodríguez-Hornedo, N.; Solubility Advantage of Pharmaceutical Cocrystals, Cryst. Growth Des. 2009, 9(5), 2252−2264.
-
Thakuria, R.; Delori, A.; Jones, W.; Lipert, M. P.; Roy, L.; Rodríguez-Hornedo, N.; Pharmaceutical cocrystals and poorly soluble drugs, Int. J. Pharm. 2013, 453 (1), 101−125.
-
Lipert, M. P.; Rodríguez-Hornedo, N.; Cocrystal Transition Points: Role of Cocrystal Solubility, Drug Solubility, and Solubilizing Agents, Mol. Pharmaceutics 2015, 12 (10), 3535−3546.
-
Huang, Y.; Zhang, B.; Gao, Y.; Zhang, J.; Shi, L.; Baicalein–Nicotinamide Cocrystal with Enhanced Solubility, Dissolution, and Oral Bioavailability, J. Pharm. Sci. 2014, 103 (8), 2330−2337.
-
Chen, Y.; Li, L.; Yao, J.; Ma, Y. Y.; Chen, J. M.; Lu, T. B.; Improving the Solubility and Bioavailability of Apixaban via Apixaban–Oxalic Acid Cocrystal, Cryst. Growth Des. 2016, 16 (5), 2923−2930.
-
Gao, Y.; Zu, H.; Zhang, J.; Enhanced dissolution and stability of adefovir dipivoxil by cocrystal formation, J. Pharm. Pharmacol. 2011, 63 (4), 483−490.
-
McNamara, D. P.; Childs, S. L.; Giordano, J.; Iarriccio, A.; Cassidy, J.; Shet, M. S.; Mannion, R.; O’Donnell, E.; Park, A.; Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API, Pharm. Res. 2006, 23 (8), 1888−1897.
-
Remenar, J. F.; Peterson, M. L.; Stephens, P. W.; Zhang, Z.;Zimenkov, Y.; Hickey, M. B.; Celecoxib:nicotinamide dissociation: using excipients to capture the cocrystal's potential, Mol. Pharmaceutics 2007, 4 (3), 386−400.
-
Karki, S.; Friščić, T.; Fabián, L.; Laity, P. R.; Day, G. M.; Jones, W.; Improving Mechanical Properties of Crystalline Solids by Cocrystal Formation: New Compressible Forms of Paracetamol, Adv. Mater. 2009, 21 (38−39), 3905−3909.